< Back to previous page
Investigation of programmed death-1 and its ligands as novel immunotherapeutic targets in malignant pleural mesothelioma.
Malignant pleural mesothelioma (MPM) is a highly aggressive and fatal cancer that affects the membranes lining the lung and is mostly associated with previous exposure to asbestos. Till today, prognosis of patients diagnosed with MPM remains dismal with a median overall survival of only 9-12 months and currently available treatment methods have only a limited impact on it. Therefore there is an urgent need for new treatment methods. During my PhD project I will investigate the immune checkpoint programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, as immunotherapeutic targets in MPM. It is presently unknown if blocking these targets have any effect in MPM but clinical trials in several tumor types have already shown promising results for PD-1 and PD-L1 immunotherapy.
Date:1 Jan 2015 → 31 Dec 2018
Keywords:MESOTHELIOMA, TUMORS, IMMUNOTHERAPY
Disciplines:Immunology, Morphological sciences, Oncology